bioAffinity Technologies (BIAF) Total Current Liabilities (2021 - 2026)

bioAffinity Technologies has disclosed Total Current Liabilities across 6 years of filings, most recently posting $3.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 6.75% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (down 6.75% YoY), while the FY2025 annual figure was $2.9 million, down 6.4% from the prior year.
• Total Current Liabilities climbed to $3.2 million in Q1 2026, from $2.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for BIAF reached as high as $3.4 million in Q1 2025 and fell as low as $775151.0 in Q2 2023.
• The 5-year median for Total Current Liabilities is $2.3 million (2024), against an average of $2.2 million.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 91.27% — and 2024, when it soared 200.11%.
• A 5-year view of Total Current Liabilities shows it stood at $1.1 million in 2022, then surged by 97.41% to $2.2 million in 2023, then soared by 38.13% to $3.1 million in 2024, then slipped by 6.4% to $2.9 million in 2025, then gained by 9.59% to $3.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $3.2 million, $2.9 million, and $2.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.